Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Hematological Oncology|April 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paperSarah Bailly, Guillaume Cartron, Sridhar Chaganti, et al.
Haematologica|August 2, 2013
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantEric Van Den Neste, Olivier Casasnovas, Marc André, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 30, 2014
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphomaChristophe Fruchart, Hervé Tilly, Franck Morschhauser, et al.
Cancers|April 12, 2022
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA GroupChristophe Bonnet, Jehan Dupuis, Hervé Tilly, et al.
Psycho-Oncology|March 20, 2017
Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort studyYves Libert, Cindy Borghgraef, Yves Beguin, et al.
Psycho-Oncology|March 5, 2016
Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: an exploratory studyYves Libert, Cindy Borghgraef, Yves Beguin, et al.
British Journal of Haematology|September 10, 2016
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective studyPhilip A Thompson, Vincent Lévy, Constantine S Tam, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
British Journal of Haematology|April 24, 2024
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study)Florence Nguyen-Khac, Marine Baron, Romain Guièze, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
Pageof 9